Trials / Completed
CompletedNCT01316237
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
A Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects with Chronic Hepatitis C Virus Infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GS-6620 | GS-6620 tablet, 50 mg QD |
| DRUG | GS-6620 | GS-6620 tablet, 100 mg QD |
| DRUG | GS-6620 | GS-6620 tablet, 300 mg QD |
| DRUG | GS-6620 | GS-6620 tablet, 100 mg QD, Fasted |
| DRUG | GS-6620 | GS-6620 tablet, 300 mg QD, Fasted |
| DRUG | GS-6620 | GS-6620 tablet, 900 mg QD, Fasted |
| DRUG | GS-6620 tablet, 450 mg BID | GS-6620 tablet, 450 mg BID |
| DRUG | GS-6620 tablet | GS-6620 tablet, 900mg , BID |
| DRUG | GS-6620 tablet | GS-6620 tablet, 900 mg |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2011-10-01
- Completion
- 2012-01-01
- First posted
- 2011-03-16
- Last updated
- 2012-03-26
Locations
13 sites across 2 countries: United States, Puerto Rico
Source: ClinicalTrials.gov record NCT01316237. Inclusion in this directory is not an endorsement.